套细胞淋巴瘤中P53基因的研究进展

套细胞淋巴瘤(mantle cell lymphoma,MCL)是2001年WHO淋巴造血组织肿瘤新分类中的一种独立的B细胞非霍奇金淋巴瘤,几乎所有的MCL都有t(11;14)(q13;q32)易位,此易位使11q13上的BCL-1癌基因(cyclin D1)与14q32上的IgH基因重排,导致cyclin D1过度表达,促进细胞由G1期进入S期而使G1期缩短。MCL临床病程和转归呈异质性,许多临床和实验室特征可影响其预后,其中P53基因的异常与MCL的病程及转归密切相关。本文就P53基因的缺失、突变与MCL的关系,P53异常患者的治疗作一综述。

Research advance of p53 gene in mantle cell lymphoma

Mantle cell lymphoma （MCL） is an independent uncommon subtype of B-cell non-Hodgkin＇s lymphoma （NHL） according to World Health Organization classification of hematopoietic and lymphoid tissue tumors. The genetic hallmark of MCL is the chromosomal translocation t（11;14） （q13; q32） that leads to upregulation of cyclin D1, an important regulator of the G1 phase in the cell cycle. This genetic aberration is virtually present in all cases of MCL. It is characterized by distinct clinical features and outcome which is affected by a series of additional genetic aberration including the genomic guardian-P53 gene. This article reviews the effects of P53 gene aberrations including P53 deletion, mutation and their mutual relationship in MCL, and novel therapeutic regimens for MCL patients with P53 aberrations.